Business

Cerus Corporation (NASDAQ: CERS) Announces Partnership with LifeSouth Community Blood Centers to produce INTERCEPT® Fibrinogen Complex

Cerus Corporation (NASDAQ: CERS) announced today an arrangement with LifeSouth Community Blood Centers to aid as a creative associate for INTERCEPT® Fibrinogen Complex, the company’s pathogen abridged cryoprecipitate fibrinogen multifaceted creation. 

LifeSouth is the fifth manufacture associate for INTERCEPT Fibrinogen Complex

LifeSouth is the fifth manufacture associate for INTERCEPT Fibrinogen Complex, permitting the preliminary commercial presentation of the product to swell into Florida.

“We are pleased to add LifeSouth as a blood center industrial associate for INTERCEPT Fibrinogen Complex,” stated Elan Weiner, general manager of Cerus Therapeutics. “The early market reaction has been passionate and as we gear up for a countrywide launch in 2022 following expected BLA endorsements, we are content to be able to offer this creation in Florida through our affiliation. Additionally, LifeSouth’s robust manifestation throughout the Southeast will help safeguard we have the capability to easily transport product to infirmaries in the area,” Mr. Weiner continued.

As the third most populated state in the country, Florida is home to more than 30 Level 1, Level 2, and Pediatric shock centers. Concurrently with the other four states that are a part of the first launch (California, Louisiana, Texas, and Wisconsin), INTERCEPT Fibrinogen Complex will be obtainable for nearly one-third of the U.S. populace.

Clover Biopharmaceuticals and Dynavax Technologies Corporation (NASDAQ: DVAX) announce commercial delivery contract of Dynavax’s CpG 1018 Adjuvant

Clover Biopharmaceuticals (Clover) and Dynavax Technologies Corporation (NASDAQ: DVAX) announced the completion of a commercial Deliver contract of Dynavax’s CpG 1018™ advanced adjuvant for use in Clover’s protein-based COVID-19 inoculation applicant, SCB-2019 (CpG 1018/Alum). 

The commercial supply contract outspreads to the end of 2022. The contract comprises amounts for distribution in 2021, contrived under the beforehand announced funding contract between Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax.

Clover individually announced today an advanced acquisition contract with Gavi, the Vaccine Alliance, for providing up to 414 million doses of SCB-2019 (CpG 1018/Alum) over 2022 for the COVAX Facility. 

The COVAX Facility is a worldwide risk-sharing contrivance for shared attaining and reasonable distribution of COVID-19 inoculations, irrespective of revenue level. Awaiting provisional governing endorsements, Clover presumes to begin product launch of SCB-2019 (CpG 1018/Alum) by the end of 2021, delivering the COVAX Facility and nations straight via government obtaining and two-pronged supply contracts.

Leave a Comment

Your email address will not be published.

*